Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$13.92 -0.10 (-0.71%)
As of: Sep 4, 2026 · 3:17 PM EDT

Enanta Pharmaceuticals (ENTA) Operating Income (QoQ) (2012 - 2026)

Analysis

Enanta Pharmaceuticals (ENTA) Operating Income (QoQ) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn -
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn -
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn
10 Enanta Pharmaceuticals 404.93 Mn 215.43 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -45.43%
Mar 31, 2026 -5.32%
Dec 31, 2025 38.80%
Sep 30, 2025 2.68%
Jun 30, 2025 22.97%
Mar 31, 2025 -4.18%
Dec 31, 2024 21.14%
Sep 30, 2024 -23.44%
Jun 30, 2024 26.19%
Mar 31, 2024 6.08%
Dec 31, 2023 -12.43%
Sep 30, 2023 15.48%
Jun 30, 2023 6.94%
Mar 31, 2023 -31.45%
Dec 31, 2022 -10.96%
Sep 30, 2022 16.88%
Jun 30, 2022 3.86%
Mar 31, 2022 -11.31%
Dec 31, 2021 9.84%
Sep 30, 2021 0.35%